Aurinia Pharmaceuticals Inc. (AUPH) FinancialsAUPHAurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (AUPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Therapeutic Drug Division, accounting for 84.6% of total sales, equivalent to $1.35M. Other significant revenue streams include Diagnostic Division and Corporate. Understanding this composition is critical for investors evaluating how AUPH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aurinia Pharmaceuticals Inc. maintains a gross margin of 92.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 55.68%, while the net margin is 44.96%. These profitability ratios, combined with a Return on Equity (ROE) of 66.12%, provide a clear picture of how effectively AUPH converts its operational activities into shareholder value.

In the context of the broader market, AUPH competes directly with industry leaders such as PVLA and URGN. With a market capitalization of $2.06B, it holds a significant position in the sector. When comparing efficiency, AUPH's gross margin of 92.12% stands against PVLA's N/A and URGN's 90.93%. Such benchmarking helps identify whether Aurinia Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Aurinia has demonstrated impressive financial growth, with total revenue reaching $83.2 million in Q2 2026, an 18.9% year-over-year increase, and net product sales of LUPKYNIS showing a 19% increase over the same period. The company has also reported a gross margin of 92.12% in Q2 2026, indicating strong profitability.